510 Results
Sort By:
Published on August 27, 2024
A new nasal COVID-19 vaccine is ready for clinical trials, said K. Anand Kumar, managing director of Indian Immunologicals and one of the co-authors of a new report on the vaccine. Called CDO-7N-1, it “induces robust mucosal and systemic neutralizing antibody and T-cell subset responses, in mice, hamsters, and macaques…
Published on August 26, 2024
A lung cancer patient at University College London Hospitals (UCLH) was the first to receive a novel mRNA-based vaccine designed to prime the immune system to fight cancer cells very specifically. The BioNTech immunotherapy (BNT116) is being studied in a worldwide lung cancer trial. The NIHR UCLH Clinical Research Facility…
Published on August 1, 2024
BioNTech’s goal of developing a cancer vaccine was boosted by positive results from a Phase II trial of its investigational mRNA immunotherapy BNT111 in combination with Regeneron’s PD-1 checkpoint inhibitor cemiplimab in advanced melanoma. The trial met its primary efficacy outcome measure with a statistically significant improvement in overall response…
Published on June 5, 2024
The first patient has received a personalized vaccine in a clinical trial as part of NHS England’s new Cancer Vaccine Launch Pad. The plan is that thousands of patients in England will gain access to personalized cancer vaccine trials through the new “matchmaking” service for patients and drug developers. Thirty…
Published on May 22, 2024
The results of two back-to-back randomized double-blind placebo controlled trials has shown that a 100-year-old vaccine originally developed to prevent tuberculosis helps protect people with type 1 diabetes from COVID-19 and other infectious diseases. The research by investigators at the Massachusetts General Hospital (MGH) found that the Bacillus Calmette-Guérin (BCG)…
Published on May 13, 2024
Takeda has signed a deal with Swiss biotech AC Immune to complete development and commercialize its Alzheimer’s amyloid-beta vaccine, which is currently in Phase I/II trials. AC Immune will receive an upfront payment of $100 million and will then be eligible for additional fees of $2.1 billion if all development,…
Published on May 10, 2024
A new treatment that combines a personalized dendritic cell vaccine with the immune-boosting substance poly-ICLC has been shown to enhance the immune response and activity of T cells in patients with malignant glioma. The addition of poly-ICLC improves dendritic cells’ ability to treat the brain tumor than the vaccine alone,…
Published on May 6, 2024
New research, led by University of Cambridge investigators, shows they have developed a new vaccine technology that provides a broad range of protection against coronaviruses, even those that don’t yet exist. This approach to vaccine development is called “proactive vaccinology,” which seeks to build disease-fighting immunity before some pathogens emerge.…
Published on May 1, 2024
Researchers at the University of Florida report they have developed an mRNA cancer vaccine that quickly reprograms the immune system to attack glioblastoma in a first-ever human clinical trial of four adult patients. Their results published in Cell mirror those from preclinical mouse studies, and from a newly reported trial…
Published on April 26, 2024
There’s new evidence the COVID-19 mRNA vaccines don’t provide much mucosal immunity, according to a team of French researchers. In a study that included more than 400 patients, there was some mucosal immunity provided by these vaccines, but previously infected people had a greater response. This suggests that new approaches,…
Published on April 24, 2024
A team of researchers led by Michigan State University (MSU) in collaboration with Harvard Medical School and the National Cancer Institute has developed a promising vaccine candidate to fight antibiotic-resistant bacteria. Using a novel vaccine delivery platform, researchers in the lab of Xuefei Huang, PhD, a professor of chemistry and…
Published on April 8, 2024
Researchers from the Memorial Sloan Kettering Cancer Center (MSKCC) have shown that an experimental investigational mRNA-based vaccine candidate shows potential to stimulate the immune system which may reduce the risk of pancreatic cancer returning after surgery. In new results from a Phase I trial, the candidate, autogene cevumeran, activated immune…
Published on April 5, 2024
German biotech CureVac has announced positive mid-Phase II data for its mRNA flu vaccine, which it is developing with big pharma GSK. While the results showed better reactivity against more severe, pandemic-associated influenza A strains than currently available vaccines, the vaccine candidate was not as effective as current vaccines against…
Published on February 7, 2024
Colorectal and pancreatic cancers—the second and third leading causes of cancer death, respectively—often have mutations in the KRAS protein. Now, a new vaccine that targets KRAS has shown encouraging early results as a potential off-the-shelf treatment for patients with pancreatic cancer or colorectal cancer, according to a study co-led by…
Published on January 30, 2024
Research led by Harvard University demonstrates that a type of virus-like DNA particle can be used to form an effective vaccine against viruses like SARS-CoV-2. To date, the prototype vaccine has only been tested in mice and not humans, as reported in Nature Communications, but a COVID vaccine made using…